GlassScriptPhysician profile
Nagamani Kurusanganapalli
NPI 1154551992
$6,339.58
in general payments reported to CMS, 2019-2025
33 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.84 · 2020: $455 · 2021: $881 · 2022: $896 · 2023: $840 · 2024: $1,537 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030 · Education: $13.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.29 |
| Education | $13.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $931.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $613.65 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $514.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $484.71 | 2019-2025 | |
| Amgen INC. | $430.83 | 2020-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $279.77 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $258.40 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $257.76 | 2022-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $174.21 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.92 | 2022-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $95.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $88.27 | 2020-2022 | |
| Almatica Pharma LLC | $87.11 | 2022-2023 | Gralise |
| Phathom Pharmaceuticals, INC. | $85.25 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $82.32 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.69 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $68.26 | 2020-2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $51.99 | 2021 | |
| Allergan, INC. | $45.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $44.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.33 | 2025 | Xifaxan |
| Corcept Therapeutics | $36.84 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $36.15 | 2021-2022 | |
| Astellas Pharma US INC | $26.69 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.53 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $19.91 | 2024 | |
| Inspire Medical Systems, INC. | $18.57 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $15.51 | 2020 | |
| Dexcom, INC. | $15.28 | 2022 | |
| Shield Therapeutics INC | $13.38 | 2023 | Accrufer |
| Biodelivery Sciences International, INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagamani Kurusanganapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.